Introduction to the antivirals against Dengue virus Volume 24, issue 4, Juillet-Août 2020


  • Figure 1

  • Figure 2

  • Figure 3


1 Sans affiliation
* Correspondance

Dengue virus (DENV) is part of the Flaviviridae family and has been classify by the Word Health Organization (WHO) as one of the top 10 health concerns. It is the most widespread mosquito-borne human disease. Considering the increasing number of severe dengue, the expansion of the vector territory due to climate change and population movement, it is urgent to find a way to counteract the virus. Indeed, currently there is no treatment available and despite the large number of molecules that proved efficacy in vitro rare are the compounds that have been further evaluated and lead to clinical trials. Development of antiviral is a promising complementary strategy to vaccine production. This review introduces the DENV antivirals and the notions of direct acting antiviral versus host targeted antiviral. It underlines the importance to develop multiple potent antivirals and the relevance to maintain research on this matter.